INDEX Holding

InDex Pharmaceuticals Holding AB is a Swedish biopharmaceutical company that focused on developing immunological therapies for severe inflammatory diseases, with a primary focus on ulcerative colitis. The company's proprietary platform is based on DNA-based ImmunoModulatory Sequences (DIMS), with the lead candidate cobitolimod acting as a first-in-class Toll-like receptor 9 (TLR9) agonist. In early 2024, the company discontinued its global Phase 3 CONCLUDE study for cobitolimod after an interim analysis indicated a low probability of meeting the primary endpoint. Following this, the company entered into a reverse merger agreement with Flerie Invest AB, transitioning its corporate focus toward Flerie's investment portfolio in the life science sector. Historically, the company's approach aimed to provide a localized, safe, and effective treatment option for patients who did not respond to conventional therapies.